Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Manchester, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV

Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 12 Oct 2026, 03:15 UTC

2863

Studies in scope

industry-sponsored, all four open statuses

1385

Recruiting now

open to new participants

542

Lead sponsors

across recruiting studies

Top sites

London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425

Trials with a site in Manchester

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Not yet open

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,180

Birmingham, London, Glasgow, Cardiff, Manchester

2027-11-23

Not yet open

Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes

NCT07401901Type 1 Diabetes (T1D)

Medtronic MiniMed, Inc.

Not applicable

230

Cambridge, Leicester, Manchester

2026-10-15

Not yet open

Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With Asthma

NCT07851623Asthma, Healthy Volunteers

Chiesi Farmaceutici S.p.A.

Phase 1

120

Leeds, London, Manchester

2026-10-01

Not yet open

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

NCT07762027Chronic Hepatitis D Infection

Assembly Biosciences

Phase 2

London, Manchester

2026-10

Recruiting

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07768189Oropharyngeal Carcinoma (OPC)

DrugsCRB-701·Cetuximab·Docetaxel

Corbus Pharmaceuticals Inc.

Phase 3

260

London, Sutton, Birmingham, Cambridge, Glasgow, Liverpool, Manchester, Nottingham

2026-09-29

Recruiting

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

466

Birmingham, Exeter, Lancaster, Leeds, Leicester, London, Manchester, Oxford

2026-09-17

Not yet open

Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients

NCT07802730COPD (Chronic Obstructive Pulmonary Disease)

AeroRx Therapeutics Inc.

Phase 1

Manchester

2026-09

Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07743463Obesity, Overweight, Chronic Weight Management

DrugASC30 A1

Ascletis Pharma (China) Co., Limited

Phase 3

3,003

Bellshill, Cardiff, Edgbaston, London, Manchester, Stoke-on-Trent, Warrington

2026-08-31

Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus

DrugASC30 A1

Ascletis Pharma (China) Co., Limited

Phase 3

1,560

Cardiff, Edgbaston, Glasgow, London, Manchester, Stoke-on-Trent, Warrington

2026-08-28

Recruiting

A Prospective Study of Pediatric Participants up to 16 Years of Age With Methylmalonic Acidemia (MMA) Due to Mutations in the MMUT Gene

NCT07432880Methylmalonic Acidemia (MMA)

Genespire Srl

Observational

London, Manchester

2026-08-13

Recruiting

A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults

NCT07764237Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV)

DrugsMRNA-1345·MRNA-1365

ModernaTX, Inc.

Phase 1

375

Manchester, Southampton, Norwich, Birmingham, London, Newcastle

2026-08-11

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease

NCT07758595Alzheimer's Disease, Healthy Participants

Denali Therapeutics Inc.

Phase 1

178

Manchester

2026-08-07

Recruiting

Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

DrugPegcetacoplan

Swedish Orphan Biovitrum

Phase 4

150

Cambridge, Cardiff, Glasgow, Leicester, London, Manchester, Newcastle, Salford

2026-08-05

Not yet open

Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

NCT07682129Duchenne Muscular Dystrophy (DMD)

DrugsENTR-601-44·ENTR-601-45

Entrada Therapeutics, Inc.

Phase 2

Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford

2026-08

Recruiting

First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults

NCT07646353Malaria, Falciparum

GlaxoSmithKline

Phase 1

Manchester

2026-07-27

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Cambridge, Edinburgh, Manchester

2026-07-10

Recruiting

EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

NCT07523581Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive

Eloxx Pharmaceuticals, Inc.

Phase 2

Liverpool, London, Manchester

2026-06-30

Recruiting

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

NCT07764978Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab

AstraZeneca

Phase 3

750

Edinburgh, London, Manchester

2026-06-26

Recruiting

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

NCT07602777Sarcoma

DrugsRis-Rez·G-Csf

GlaxoSmithKline

Phase 1/2

Manchester, London

2026-06-22

Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Immuneering Corporation

Phase 3

510

London, Manchester

2026-06-05

Recruiting

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

NCT07359820FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult

Elevar Therapeutics

Phase 2

London, Manchester

2026-06-04

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

Leicester, Liverpool, London, Manchester, Montacute

2026-05-21

Recruiting

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480Myelodysplastic Syndrome, Anemia

DrugsElritercept·Epoetin Alfa

Takeda

Phase 3

300

Leicester, Boston, Oxford, Birmingham, London, Manchester

2026-05-21

Recruiting

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 2

Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield

2026-05-20

Recruiting

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

NCT07572006Hematologic Neoplasms

Janssen Research & Development, LLC

Phase 1

360

Manchester

2026-05-13

Recruiting

A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies

NCT07613723Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer

DrugsFludarabine·Cyclophosphamide

Zelluna Immunotherapy AS

Phase 1

London, Manchester

2026-05-11

Recruiting

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

NCT07549412Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Bevacizumab

EMD Serono Research & Development Institute, Inc.

Phase 3

1,020

Aberdeen, Manchester, London

2026-05-06

Recruiting

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

NCT07427394Advanced Breast Cancer

DrugsAtirmociclib·Camizestrant

AstraZeneca

Phase 2

Cambridge, London, Manchester

2026-05-06

Recruiting

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

NCT07509151Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

DrugSurovatamig

AstraZeneca

Phase 3

420

Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton

2026-05-05

Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

DrugMK-1045

Merck Sharp & Dohme LLC

Phase 1/2

280

Plymouth, Manchester

2026-05-03

Recruiting

Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)

NCT07567131Erythropoietic Protoporphyria (EPP), X-Linked Porphyria (XLP)

Portal Therapeutics, Inc.

Observational

Cardiff, Dundee, London, Manchester

2026-04-30

By invitation

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

NCT07393373Hypochondroplasia

DrugInfigratinib

QED Therapeutics, a BridgeBio company

Phase 2

135

Manchester, Sheffield, Glasgow

2026-04-23

Recruiting

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

NCT07441876Achondroplasia

DrugVosoritide

BioMarin Pharmaceutical

Phase 2/3

160

Bristol, Glasgow, Liverpool, London, Manchester

2026-04-20

Recruiting

Visugromab in Cachexia International Trial

NCT07112196Cancer-associated Cachexia

DrugsVisugromab·Visugromab RDE

CatalYm GmbH

Phase 2/3

518

Brighton, Cambridge, Dundee, Edinburgh, Guildford, Manchester, Newcastle upon Tyne

2026-04-16

Recruiting

Controlling Hyperactive Immunity With Long-lived Lymphocytes

NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease

Quell Therapeutics Limited

Phase 1/2

Birmingham, Leeds, London, Manchester, Newcastle, Oxford

2026-04-10

Recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07522073Solid Tumors

DrugINCB161734

Incyte Corporation

Phase 3

588

Dundee, Guildford, Headington, Leeds, London, Manchester, Northwood, Norwich

2026-04-09

Recruiting

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

NCT07405801Breast Cancer

DrugsInavolisib·Ribociclib·Fulvestrant

Hoffmann-La Roche

Phase 2

Leicester, London, Manchester

2026-04-07

Recruiting

PS-002 for the Treatment of IgA Nephropathy in Adults

NCT07182227Immunoglobulin A (IgA) Nephropathy

Purespring Therapeutics Limited

Phase 1/2

Manchester, Leicester, Nottingham, Bristol, Cardiff, Edinburgh, London

2026-03-30

Recruiting

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

NCT07571746Primary Membranous Nephropathy

DrugSurovatamig

AstraZeneca

Phase 2

London, Manchester

2026-03-28

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

NCT07293351Advanced Renal Cell Carcinoma (RCC)

DrugsCasdatifan·Pumitamig·Cabozantinib·Yervoy

Bristol-Myers Squibb

Phase 1/2

474

London, Preston, Cambridge, Cardiff, Edinburgh, Manchester, Sulton, Surrey

2026-03-26

Recruiting

A Long-Term Observational Study of Patients With Fucosidosis

NCT07615400Fucosidosis

JCR Pharmaceuticals Co., Ltd.

Observational

Belfast, Birmingham, London, Manchester, Salford

2026-03-25

Recruiting

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms

DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab

Merck Sharp & Dohme LLC

Phase 3

450

Glasgow, London, Manchester

2026-03-23

Recruiting

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

NCT07387367Adenovirus Infections

SymBio Pharmaceuticals

Phase 3

180

Birmingham, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield, Sutton

2026-03-17

Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497Non-small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Durvalumab

Bristol-Myers Squibb

Phase 3

850

Manchester, Newcastle upon Tyne, Birmingham, Cambridge, Cardiff, Guildford, Leeds, Liverpool

2026-03-16

Not yet open

Evaluating the Safety and Clinical Efficacy of the BAIBYS™ System in Intracytoplasmic Sperm Injection (ICSI)

NCT06990906Male Infertility, Azoospermia

BAIBYS Fertility

Not applicable

260

Manchester

2026-03-15

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

DrugsPumitamig·Folfox·Nivolumab

Bristol-Myers Squibb

Phase 2/3

690

London, Oxford, Sutton, Glasgow, Manchester

2026-03-13

Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsCetuximab·Nab-paclitaxel·Gemcitabine

Revolution Medicines, Inc.

Phase 3

900

Torquay, Birmingham, Cambridge, Liverpool, London, Manchester

2026-03-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Bristol, Cardiff, Leeds, London, Maidstone, Manchester, Sutton

2026-03-05

Recruiting

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

NCT05570422Cervical Cancer

DrugsKortuc·Cisplatin

Kortuc, Inc.

Phase 1

Manchester

2026-03-01

Recruiting

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

NCT07454837Chronic Hepatitis D

DrugBulevirtide

Mirum Pharmaceuticals, Inc.

Phase 2/3

120

Cottingham, Cardiff, London, Manchester

2026-02-26

Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07335497Locally Advanced / Metastatic Solid Tumors

Crescent Biopharma, Inc.

Phase 1/2

290

Manchester

2026-02-17

Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558Ovarian Neoplasms, Ovarian Cancer

DrugsMvasi·Sacituzumab tirumotecan·Avastin·Bevacizumab

Merck Sharp & Dohme LLC

Phase 3

900

Cambridge, Leicester, London, Manchester

2026-02-16

Recruiting

A Study of Brenipatide in Participants With Opioid Use Disorder

NCT07420283Opioid Use Disorder

DrugsBuprenorphine·Brenipatide

Eli Lilly and Company

Phase 2

465

Chertsey, Doncaster, Eastbourne, Glasgow, London, Manchester, Milton Keynes, Southampton

2026-02-13

Recruiting

RIG 101 Trial in Healthy Adults and Adults With Asthma

NCT07488897Healthy Adult Participants, Asthma Exacerbation, Safety and Efficacy

RIGImmune Inc.

Phase 1/2

London, Manchester

2026-02-09

Recruiting

Surgical Procedure Efficiency Evaluation stuDy

NCT07228091Cataract, Vitreous Hemorrhage, Retinal Detachment, Macular Pucker

Alcon Research

Observational

180

Manchester

2026-02-09

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

NCT07321886Obesity, Overweight

DrugEloralintide

Eli Lilly and Company

Phase 3

1,980

Blackpool, Bradford on Avon, Lancashire, Lancaster, Londonderry, Manchester, Peterborough, Romsey

2026-02-06

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Cambridge, Dundee, Leeds, London, Manchester, Oxford

2026-02-03

Not yet open

International Study on Treatment of Liver (HCC) Patients With IRE

NCT07192731Hepatocellular Carcinoma (HCC), Liver Ablation, Liver Cancer, Adult

Angiodynamics, Inc.

Not applicable

Manchester

2026-02

Not yet open

International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE

NCT07191548Colorectal Adenocarcinoma Metastatic in the Liver, Liver Ablation, Liver Cancer, Adult

Angiodynamics, Inc.

Not applicable

Manchester

2026-02

Recruiting

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

NCT07080385Autosomal Dominant Hypocalcemia Type 1 (ADH1)

DrugEncaleret

Calcilytix Therapeutics, Inc., a BridgeBio company

Phase 2/3

London, Manchester

2026-01-30

Recruiting

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia

DrugAtumelnant

Crinetics Pharmaceuticals Inc.

Phase 2/3

153

Liverpool, London, Manchester, Sheffield

2026-01-22

Recruiting

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

NCT07053800Lupus Nephritis

DrugObecabtagene autoleucel

Autolus Limited

Phase 2

Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester

2026-01-16

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab

Boehringer Ingelheim

Phase 3

400

Cardiff, Edinburgh, London, Manchester, Sutton

2026-01-16

Recruiting

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

240

Cambridge, Glasgow, Manchester

2026-01-15

Recruiting

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

NCT07319871Prostatic Neoplasms

DrugsJNJ-86974680·Pasritamig

Janssen Research & Development, LLC

Phase 1

Manchester, Sutton

2026-01-14

Recruiting

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes

DrugPosaconazole

AstraZeneca

Phase 1/2

Edinburgh, London, Manchester, Newcastle

2026-01-09

Recruiting

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

NCT06904261Fabry Disease

DrugMigalastat HCl

Amicus Therapeutics

Phase 3

London, Manchester

2026-01-08

Recruiting

Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening

NCT07219277Breast Cancer, Liquid Biopsy, Early Detection

Syantra Inc.

Observational

2,000

Manchester

2026-01-07

Recruiting

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

NCT07033598Leukemia, Myelomonocytic, Chronic

DrugsPacritinib·Hydroxyurea

Theradex

Phase 2

London, Manchester

2026-01-01

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer

DrugsPumitamig·Folfox·Bevacizumab

Bristol-Myers Squibb

Phase 2/3

990

Norwich, Manchester, Metropolitan Borough of Wirral, Oxford, Guildford, Birmingham, Cardiff, Dorchester

2025-12-31

Active, closed

Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR

NCT06824129Complicated Urinary Tract Infection

QIAGEN Gaithersburg, Inc

Observational

1,500

Manchester

2025-12-23

Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NCT07174336Breast Neoplasms, Neoplasm Metastasis

DrugsTersolisib·Exemestane·Anastrozole·Abemaciclib

Eli Lilly and Company

Phase 3

800

Edinburgh, Huddersfield, London, Manchester, Plymouth, Worcester

2025-12-22

Active, closed

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

360

Manchester, Nottingham, Torquay, Cardiff

2025-12-22

Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

480

London, Manchester

2025-12-17

Recruiting

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

NCT07301736Asthma

Chiesi Farmaceutici S.p.A.

Phase 2

780

Belfast, Bristol, Dagenham, London, Maidstone, Manchester, Orpington, Portsmouth

2025-12-17

Recruiting

FeetSee Thermal Images Collection Protocol in Diabetes Patients

NCT07300163Diabetic Foot Ulcer

Diabetis JSC

Observational

100

Blackpool, Lancaster, Manchester

2025-12-16

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

DrugCetuximab

Revolution Medicines, Inc.

Phase 3

500

Birmingham, Glasgow, Liverpool, London, Manchester

2025-12-15

Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

DrugsVepugratinib·Pembrolizumab

Eli Lilly and Company

Phase 3

450

Huddersfield, London, Manchester, Sheffield

2025-12-12

Recruiting

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia

DrugAtumelnant

Crinetics Pharmaceuticals Inc.

Phase 3

150

Cardiff, London, Manchester, Sheffield

2025-12-11

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib

AbbVie

Phase 2/3

490

London, Manchester

2025-12-10

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Birmingham, Glasgow, Greater London, Leeds, London, Manchester

2025-12-04

Recruiting

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

NCT07209111Neoplasm Malignant

DrugsCalderasib·Cetuximab

Merck Sharp & Dohme LLC

Phase 2

150

London, Manchester

2025-12-04

Recruiting

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691Carcinoma, Non-Small-Cell Lung

Janssen Research & Development, LLC

Observational

380

Bath, Cardiff, Eastbourne, Guildford, Heath Town, London, Manchester, Sutton

2025-12-03

Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926Gastrointestinal Neoplasms

DrugsIDRX-42·Sunitinib

GlaxoSmithKline

Phase 3

450

Manchester, Edinburgh, Cambridge, Leeds, London, Sheffield

2025-12-03

Recruiting

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Alexion Pharmaceuticals, Inc.

Phase 2

Birmingham, Cambridge, Leicester, London, Manchester

2025-11-26

Recruiting

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

NCT07073950Chronic Obstructive Pulmonary Disease, Hyperinflation

AstraZeneca

Phase 4

Harefield, London, Manchester

2025-11-24

Recruiting

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

NCT07247084Obesity

DrugTirzepatide

Eli Lilly and Company

Phase 4

3,000

Altrincham, Ashton-under-Lyne, Bolton, Bury, Cheshire, Great Lever, Hyde SK14, Manchester

2025-11-24

Recruiting

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279Achondroplasia

QED Therapeutics, a BridgeBio company

Phase 2

Glasgow, Manchester, Sheffield

2025-11-19

Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832Metastatic Colorectal Cancer (CRC)

DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin

Summit Therapeutics

Phase 3

600

Canterbury, London, Aberdeen, Edinburgh, Liverpool, Manchester

2025-11-18

Recruiting

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842Advanced Solid Cancers

BioNTech SE

Phase 1/2

245

Leeds, London, Manchester, Newcastle upon Tyne, Sutton

2025-11-18

Active, closed

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,060

Bath, Birmingham, Edinburgh, Glasgow, London, Manchester, Oxford, Preston

2025-11-12

Recruiting

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)

AstraZeneca

Phase 1/2

Bloomsbury, Manchester

2025-11-12

Recruiting

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

NCT07215585Large B-cell Lymphoma

DrugsR-mini-CHOP·Surovatamig

AstraZeneca

Phase 3

420

Glasgow, Scotland, London, Manchester, Newcastle upon Tyne, Nottingham

2025-11-11

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

Cardiff, Leicester, Manchester, Sutton, Torquay

2025-11-07

Recruiting

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

NCT07064122Haematologic Neoplasms

AstraZeneca

Phase 1

London, Manchester

2025-11-03

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Bath, Leeds, London, Manchester, Torquay

2025-10-22

Recruiting

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura

DrugEfgartigimod

argenx

Phase 2/3

Cardiff, Glasgow, Manchester

2025-10-20

Recruiting

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

NCT07219966Alcohol Use Disorder

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,100

Blackpool, Chester, Eastbourne, Edinburgh, Glasgow, London, Manchester, Southampton

2025-10-15

Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

NCT07221500Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

DrugBexobrutideg

Nurix Therapeutics, Inc.

Phase 2

100

Headington, London, Manchester

2025-10-15

Recruiting

Automation of Oocyte and Embryo Vitrification

NCT07197983Infertility

Conceivable Life Sciences

Not applicable

125

Manchester

2025-10-14

Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06988488Multiple Myeloma

DrugsMezigdomide·Elranatamab·Dexamethasone

Celgene

Phase 1/2

London, Manchester

2025-10-07

Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 3

1,280

London, Manchester, Bellshill, Birmingham, Cardiff, Liverpool

2025-10-02

Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614Prostate Cancer

AstraZeneca

Phase 1/2

Cambridge, Manchester

2025-09-30

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

London, Manchester

2025-09-29

Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

1,000

Blackburn, Cardiff, Plymouth, Torquay, London, Maidstone, Manchester

2025-09-28

Recruiting

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

NCT07176689Desmoid Tumor, Aggressive Fibromatosis

DrugNirogacestat

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 4

Cambridge, London, Manchester

2025-09-17

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

Truro, London, Belfast, Manchester, Nottingham

2025-09-11

Recruiting

European Real-World Registry for Use of the Ion Endoluminal System

NCT06923774Pulmonary Nodule, Lung Cancer

Intuitive Surgical

Observational

1,200

London, Manchester

2025-09-09

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Cambridge, Cottingham, Exeter, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne

2025-09-08

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Birmingham, London, Manchester, Sutton

2025-09-02

Recruiting

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

NCT07038824Duchenne Muscular Dystrophy (DMD)

DrugENTR-601-45

Entrada Therapeutics, Inc.

Phase 1/2

Leeds, Liverpool, London, Manchester, Oxford

2025-08-30

Recruiting

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT07200908Chronic Hepatitis D Infection

DrugBulevirtide

Mirum Pharmaceuticals, Inc.

Phase 3

172

Birmingham, London, Manchester, Cottingham

2025-08-27

Recruiting

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer

DrugsCapivasertib·Fulvestrant

Relay Therapeutics, Inc.

Phase 3

540

Bath, Cardiff, London, Manchester, Nottingham, Swindon, Truro

2025-08-26

Recruiting

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244Healthy

DrugPrevnar 20

Pfizer

Phase 3

6,000

Bristol, London, Manchester, Truro, Southampton, Oxford, Shropshire, Leeds

2025-08-25

Recruiting

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer

Pfizer

Phase 1

540

London, Manchester

2025-08-20

Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232Advanced Solid Tumor

DrugsBNT326·Paroxetine·Itraconazole·Pumitamig

BioNTech SE

Phase 1/2

1,438

Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton

2025-08-12

Recruiting

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease

Abcentra

Phase 2

240

London, Manchester, Oxford, Bath, Sheffield

2025-08-11

Recruiting

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

NCT06979596Malignant Neoplasm

DrugsOpevesostat·Tamoxifen·Exemestane·Letrozole

Merck Sharp & Dohme LLC

Phase 2

250

East Sussex, Truro, London, Edinburgh, Birmingham, Manchester

2025-08-11

Active, closed

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

NCT07142811Viral Hepatitis

DrugsTobevibart·Elebsiran·Bulevirtide

Vir Biotechnology, Inc.

Phase 2

100

London, Manchester, Nottingham

2025-08-05

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Bebington, Canterbury, Derby, London, Manchester, Northwood, Truro

2025-08-01

Active, closed

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

NCT07128550Viral Hepatitis

DrugsTobevibart·Elebsiran·Bulevirtide

Vir Biotechnology, Inc.

Phase 3

150

London, Manchester, Nottingham

2025-07-30

Recruiting

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

NCT07144137Geographic Atrophy Secondary to Age-related Macular Degeneration

Complement Therapeutics

Observational

Gloucester, London, Southampton, Sunderland, Belfast, Frimley, Manchester

2025-07-30

Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502Follicular Lymphoma

DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine

Celgene

Phase 3

400

Cringleford, Canterbury, London, Manchester

2025-07-28

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone

AbbVie

Phase 1/2

325

Manchester

2025-07-23

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

Truro, Sheffield, Southampton, Northwood, London, Taunton, Ipswich, Manchester

2025-07-23

Recruiting

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

NCT07001280Hereditary Angioedemas

CSL Behring

Observational

200

Cambridge, London, Manchester, Cardiff, Frimley, Birmingham, Leeds

2025-07-21

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

London, Leicester, Manchester

2025-07-21

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Manchester, London, Edinburgh, Oxford, Birmingham, Leeds, Motherwell, Sheffield

2025-07-21

Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

NCT07049926Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 1/2

140

Edinburgh, Glasgow, London, Cardiff, Manchester

2025-07-20

Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT07079631Metastatic Colorectal Cancer

DrugsBNT314·Pumitamig·Bevacizumab

BioNTech SE

Phase 1/2

482

London, Manchester, Sutton

2025-07-18

Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

DrugsNeladalkib·Alectinib

Nuvalent Inc.

Phase 3

450

Cambridge, Guildford, Hampstead, London, Maidstone, Manchester, Nottingham

2025-07-17

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsBevacizumab biosimilar·Calderasib·Mvasi·Erbitux

Merck Sharp & Dohme LLC

Phase 3

477

Birmingham, London, Oxford, Coventry, Cardiff, Manchester

2025-07-16

Recruiting

ELEVATE-HFpEF Clinical Study

NCT06678841Heart Failure With Preserved Ejection Fraction (HFpEF)

Medtronic Cardiac Rhythm and Heart Failure

Not applicable

700

Leeds, London, Manchester

2025-07-09

Recruiting

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

NCT07082920Prostatic Neoplasms

DrugsARX517·JNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 1

140

Manchester, Sutton

2025-07-07

Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903Transthyretin Amyloidosis With Cardiomyopathy

DrugNucresiran

Alnylam Pharmaceuticals

Phase 3

1,750

Bellshill, Birmingham, Cardiff, London, Manchester

2025-07-02

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07054515Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis

DrugNizubaglustat

Azafaros B.V.

Phase 3

147

London, Manchester

2025-06-30

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

NCT07082725Niemann-Pick Type C Disease

DrugNizubaglustat

Azafaros B.V.

Phase 3

London, Manchester

2025-06-30

Active, closed

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

NCT06794554Chronic Pulmonary Aspergillosis

Mundipharma Research Limited

Phase 2

Cambridge, Derby, Dundee, Edinburgh, Leeds, London, Manchester

2025-06-30

Recruiting

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

NCT07037862Duchenne Muscular Dystrophy (DMD)

DrugENTR-601-44

Entrada Therapeutics, Inc.

Phase 1/2

Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford

2025-06-30

Recruiting

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

NCT06998524Von Willebrand Disease, Type 3

DrugEmicizumab

Hoffmann-La Roche

Phase 3

London, Manchester

2025-06-27

Active, closed

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919Allergy, Peanut Allergy

DBV Technologies

Phase 3

480

Glasgow, Leicester, London, Manchester, Sheffield, Southampton

2025-06-24

Recruiting

Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge

NCT07059767Asthma (Diagnosis)

Ethris GmbH

Phase 2

London, Manchester

2025-06-24

Recruiting

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

NCT06464926Nausea, Vomiting

Enterra Medical, Inc.

Not applicable

148

London, Manchester

2025-06-23

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

961

Manchester, Portsmouth, Uxbridge, Bedford, Corby, Dagenham, Edinburgh, Glasgow

2025-06-23

Active, closed

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

NCT06736990Idiopathic Pulmonary Fibrosis

Calluna Pharma AS

Phase 2

150

Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton

2025-06-20

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

London, North Finchley, Glasgow, Manchester, Oxford, Birmingham, Stockport

2025-06-17

Recruiting

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

NCT06885034Gastrointestinal Neoplasms

DrugRisvutatug rezetecan

GlaxoSmithKline

Phase 1/2

451

Manchester

2025-06-11

Recruiting

PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]

NCT06923111Sickle Cell Disease

Nova Laboratories Limited

Observational

180

Basildon, Cardiff, London, Manchester, Oxford

2025-06-09

Recruiting

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867Myelodysplastic Syndromes

DrugMomelotinib

GlaxoSmithKline

Phase 2

Boston, London, Manchester

2025-06-05

Recruiting

EURO-STIM Registry

NCT06971796Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA)

Inspire Medical Systems, Inc.

Observational

1,000

London, Manchester

2025-05-26

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Cottingham, Bristol, Cardiff, Coventry, Dundee, Glasgow, London, Manchester

2025-05-22

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester

2025-05-22

Active, closed

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

NCT06940830Hemophilia A

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 4

252

Birmingham, Cardiff, London, Manchester

2025-05-21

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581Asthma

DrugTilrekimig

Pfizer

Phase 2

252

Bradford, Cambridge, Manchester, London, Crumpsall, Wakefield

2025-05-20

Recruiting

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737Lymphoma

DrugsDuvelisib·Bendamustine·Gemcitabine

SecuraBio

Phase 3

124

Sutton, Glasgow, Leicester, London, Manchester, Nottingham, Oxford

2025-05-19

By invitation

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

NCT06914908Chronic Rhinosinusitis With Nasal Polyps

DrugsLunsekimig·Mometasone furoate

Sanofi

Phase 2

Gloucester, Manchester, Newcastle upon Tyne

2025-05-12

Active, closed

A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors

NCT06932952Solid Tumor

DrugsBYON4228·Pembrolizumab

Byondis B.V.

Phase 1

Manchester, Sutton

2025-05-07

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Cambridge, Leeds, London, Manchester

2025-05-06

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

DrugsCetuximab·Docetaxel

Revolution Medicines, Inc.

Phase 3

590

London, Liverpool, Sutton, Manchester

2025-05-06

Recruiting

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

NCT06892548Advanced Lung Cancer

DrugsBNT324·Pumitamig

BioNTech SE

Phase 1/2

594

Bristol, Leeds, Liverpool, London, Manchester, Preston

2025-05-02

Active, closed

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)

DrugsPelacarsen·Inclisiran

Novartis Pharmaceuticals

Phase 3

246

Chichester, London, Manchester, Tyne and Wear

2025-04-30

Active, closed

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

NCT06883240Von Willebrand Disease, Type 3

DrugsActivated Prothrombin Complex·Recombinant Factor VIIa

Hoffmann-La Roche

Observational

London, Manchester

2025-04-29

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

London, Birmingham, Guildford, Manchester

2025-04-24

Recruiting

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463Metastatic Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Panitumumab·Fluorouracil·Leucovorin

AbbVie

Phase 2

390

London, Oxford, Sutton, Manchester

2025-04-24

Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer

DrugPumitamig

BioNTech SE

Phase 1/2

380

Cambridge, Cardiff, Leeds, London, Manchester, Sutton

2025-04-23

By invitation

An Interventional Study of Infigratinib in Children With Hypochondroplasia

NCT06873035Hypochondroplasia

DrugInfigratinib

QED Therapeutics, a BridgeBio company

Phase 2/3

Manchester, Sheffield, Glasgow

2025-04-22

Recruiting

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401Major Depressive Disorder

DrugNBI-1065845

Neurocrine Biosciences

Phase 3

850

Southampton, Sheffield, London, Manchester

2025-04-16

Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

NCT06843447Ovarian Cancer Recurrent

DrugsMK-2010·R-DXd·Zirabev·Pegylated liposomal doxorubicin

Merck Sharp & Dohme LLC

Phase 1/2

605

Brighton, Fulham, Sutton, London, Manchester

2025-04-15

Recruiting

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)

DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan

Gilead Sciences

Phase 3

695

Manchester

2025-04-04

Active, closed

Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel Plus

NCT06820060Meningitis, Encephalitis Infection

QIAGEN Gaithersburg, Inc

Observational

1,500

Manchester

2025-04-03

Active, closed

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

NCT07108166COPD, Smoking, Tobacco Use

Philip Morris Products S.A.

Not applicable

290

Enfield, Glasgow, High Wycombe, London, Manchester, Metropolitan Borough of Wirral, Preston, Rochdale

2025-04-02

Recruiting

AZD5305 hADME in Patients With Advanced Solid Malignancies

NCT06713369Locally Advanced or Metastatic Solid Tumor

DrugSaruparib

AstraZeneca

Phase 1

Liverpool, Manchester

2025-04-02

Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450Advanced Solid Tumors Cancer, MSI-H Cancer

Nimbus Wadjet, Inc.

Phase 1/2

134

London, Manchester

2025-03-31

Recruiting

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

NCT06830759Diffuse Large B-cell Lymphoma, Follicular Lymphoma

AbbVie

Observational

700

Milton Keynes, Truro, Cheltenham, Portsmouth, Airdrie, Nottingham, Manchester, Newcastle upon Tyne

2025-03-28

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Birmingham, East Sussex, Huddersfield, London, Manchester, Torquay

2025-03-27

Active, closed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

NCT06920901Asthma

DrugAPG777

Apogee Therapeutics, Inc.

Phase 1

Bradford, Manchester

2025-03-27

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Bath, Cambridge, Leeds, London, Manchester, Northwood, Taunton

2025-03-27

Recruiting

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

NCT06644781Esophageal Squamous Cell Carcinoma

DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel

Daiichi Sankyo

Phase 3

510

Belfast, Dundee, London, Manchester, Plymouth

2025-03-27

Recruiting

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

NCT06914128MTAP-deleted Solid Tumors

Bayer

Phase 1/2

450

Manchester, Sutton

2025-03-21

Active, closed

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsEfti·Pemetrexed·Keytruda·Paclitaxel

Immutep S.A.S.

Phase 3

756

Birmingham, Guildford, Manchester

2025-03-21

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007Ovarian Cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Daiichi Sankyo

Phase 3

582

Cambridge, London, Manchester, Oxford, Sheffield

2025-03-19

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290ANCA Associated Vasculitis (AAV)

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

126

Cambridge, Glasgow, London, Manchester

2025-03-13

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Glasgow, Northwood, London, Manchester

2025-03-13

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Cambridge, London, Oxford, Manchester, Newcastle upon Tyne, Sheffield

2025-03-12

Active, closed

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

NCT06903338Viral Hepatitis

DrugsTobevibart·Elebsiran

Vir Biotechnology, Inc.

Phase 3

124

London, Manchester, Nottingham

2025-03-12

Recruiting

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Cambridge, London, Manchester, Metropolitan Borough of Wirral

2025-03-12

Recruiting

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT06668181Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

Bristol, Manchester, Nottingham, Stoke-on-Trent

2025-03-11

Recruiting

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

NCT06841055Non-small Cell Lung Cancer

DrugsPumitamig·Docetaxel

BioNTech SE

Phase 2

Cardiff, Leeds, London, Manchester

2025-03-03

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Cambridge, Coventry, Dundee, London, Manchester, Sutton

2025-03-01

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137Small Cell Lung Cancer

DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab

Merck Sharp & Dohme LLC

Phase 1/2

327

London, Liverpool, Manchester

2025-02-27

Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer

DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

726

Birmingham, Cardiff, Dundee, Hull, Leeds, London, Londonderry, Manchester

2025-02-27

Active, closed

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

NCT06745323Small Cell Lung Cancer (SCLC)

DrugTarlatamab

Amgen

Phase 2

252

Manchester

2025-02-26

Recruiting

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

NCT07558668Moderate to Severe Atopic Dermatitis

Sitryx Therapeutics Ltd

Phase 1

149

Manchester, Merthyr Tydfil

2025-02-26

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276Extensive-Stage Small Cell Lung Cancer

DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin

Bristol-Myers Squibb

Phase 3

530

Central Middlesbrough, Aberdeen, Manchester, Metropolitan Borough of Wirral

2025-02-25

Active, closed

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

Leeds, London, Manchester

2025-02-19

Recruiting

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 3

256

Manchester, Oxford

2025-02-10

Recruiting

Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

NCT06487273Non-cystic Fibrosis Bronchiectasis

Physio-Assist

Not applicable

622

Belfast, Birmingham, Edinburgh, Manchester, Newcastle upon Tyne

2025-02-03

Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355Extensive-stage Small-cell Lung Cancer

DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin

BioNTech SE

Phase 3

621

Manchester, Chelsea, Sutton, Huddersfield, Newcastle upon Tyne, Nottingham, Oxford, Dundee

2025-02-03

Recruiting

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563Glioblastoma

DrugsTemozolomide·Keytruda·Pembrolizumab

NovoCure GmbH

Phase 3

741

London, Northwood, Birmingham, Cambridge, Cardiff, Edinburgh, Liverpool, Manchester

2025-02-03

Active, closed

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

NCT06809595Generalized Anxiety Disorder

DrugDT120

Definium Therapeutics US, Inc.

Phase 3

245

Glasgow, Gosforth, London, Manchester, Sheffield

2025-01-29

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Aberdeen, Birmingham, Cambridge, Glasgow, Leeds, Liverpool, London, Manchester

2025-01-28

Recruiting

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

NCT06789172Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer

DrugFamotidine

Epkin

Phase 1

146

Glasgow, Leicester, London, Manchester, Oxford

2025-01-23

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone

Incyte Corporation

Phase 3

240

Bristol, Glasgow, Leeds, London, Manchester, Nottingham, Plymouth

2025-01-21

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

NCT06667687Non-Hodgkin's Lymphoma

AbbVie

Phase 1

Manchester, Plymouth

2025-01-16

Recruiting

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126Melanoma, Cutaneous Malignant

DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine

Immatics US, Inc.

Phase 3

360

Cambridge, Glasgow, London, Manchester, Oxford, Southampton

2025-01-14

Active, closed

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06618001Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms

Janssen Research & Development, LLC

Phase 1

Cambridge, London, Manchester

2025-01-14

Recruiting

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226Sickle Cell Disease, Thalassemia

Novo Nordisk A/S

Phase 3

480

London, Manchester, Sheffield

2025-01-10

Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 2

480

Greater London, Liverpool, London, Manchester, Sutton, Torquay

2024-12-16

Active, closed

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma

DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine

Arcus Biosciences, Inc.

Phase 3

610

Birmingham, Cottingham, London, Manchester

2024-12-13

Recruiting

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT06669247Relapsed/Refractory Multiple Myeloma

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

186

London, Manchester

2024-12-11

Active, closed

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

NCT06588686Idiopathic Pulmonary Fibrosis (IPF)

Vicore Pharma AB

Phase 2

378

Birmingham, Exeter, London, Manchester, Oxford

2024-12-09

Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

NCT06534437Non-Hodgkin Lymphoma, B-cell

DrugGlofitamab

Ryvu Therapeutics SA

Phase 2

178

Glasgow, Manchester, Plymouth, Sutton, Tooting

2024-12-05

Recruiting

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

NCT06603844Solid Tumor

Corbus Pharmaceuticals Inc.

Phase 1/2

156

Newcastle upon Tyne, Manchester, Birkenhead, Edinburgh, Glasgow, London

2024-12-04

By invitation

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

700

Bellshill, Birmingham, Cardiff, Hexham, London, Manchester

2024-12-03

Recruiting

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245Patients With Non-Small Cell Lung Cancer

DrugsTedopi·Docetaxel

OSE Immunotherapeutics

Phase 3

363

Leicester, Manchester, Metropolitan Borough of Wirral, Sutton, Aberdeen

2024-12-03

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne

2024-11-27

Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

DrugSurovatamig

AstraZeneca

Phase 2

270

London, Manchester, Norwich, Nottingham, Plymouth

2024-11-27

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

Glasgow, London, Manchester, Nottingham, Plymouth

2024-11-25

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Birmingham, Harrow, London, Maidstone, Manchester, Oxford, Torquay

2024-11-19

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne

2024-11-18

Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587Solid Tumor

Genentech, Inc.

Phase 1

410

Edinburgh, London, Manchester, Sutton

2024-11-14

Recruiting

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

NCT06659341Advanced Solid Tumors Harboring KRAS G12C Mutation

Bayer

Phase 1

104

Manchester, Sutton

2024-11-08

Recruiting

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT06451770Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia

Verve Therapeutics, Inc.

Phase 1

Liverpool, London, Manchester

2024-10-30

Active, closed

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

NCT06653153Alzheimer's Disease

DrugRemternetug

Eli Lilly and Company

Phase 3

1,400

Bath, Birmingham, Blackpool, Edinburgh, London, Manchester, Motherwell, Plymouth

2024-10-24

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth

2024-10-21

Recruiting

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860Diabetic Peripheral Neuropathic Pain

DrugPregabalin

Vertex Pharmaceuticals Incorporated

Phase 2

300

Birmingham, Dundee, Glasgow, Liverpool, London, Manchester, Nuneaton, Sheffield

2024-10-18

Active, closed

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

NCT06637371Asthma

DrugAMG 691

Amgen

Phase 1

Cambridge, London, Manchester

2024-10-16

Active, closed

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

NCT06504394Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory

Drugs) Berahyaluronidase alfa·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

Bodelwyddan, London, Oxford, Manchester

2024-10-14

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

Dundee, London, Manchester

2024-10-11

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Exeter, Dundee, Larbert, Glasgow, London, Leicester, Manchester, Metropolitan Borough of Wirral

2024-10-07

Active, closed

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

NCT06513312Pre-Exposure Prophylaxis of HIV Infection

DrugsEmtricitabine/tenofovir disoproxil fumarate·F/TDF·Lenacapavir

Gilead Sciences

Phase 2

268

Birmingham, Brighton, Liverpool, London, Manchester

2024-10-07

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

Birmingham, Cambridge, Glasgow, Leicester, London, Manchester, Middlesbrough

2024-10-04

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

Edinburgh, Glasgow, London, Manchester, Newcastle upon Tyne

2024-09-30

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Cambridge, Cardiff, London, Manchester, Newcastle upon Tyne, Northwood, Southampton, Sutton

2024-09-25

Active, closed

A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

NCT06540391Melanoma

DrugsVancomycin·Keytruda·Pembrolizumab

Microbiotica Ltd

Phase 1

Brighton, Cambridge, Glasgow, London, Manchester, Newcastle, Sutton

2024-08-28

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884Multiple Myeloma

DrugsRamantamig·Talquetamab

Janssen Research & Development, LLC

Phase 2

210

Belfast, Colchester, Eastbourne, Liverpool, London, Manchester, Newcastle upon Tyne

2024-08-26

Recruiting

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin

AstraZeneca

Phase 2

257

Cambridge, Glasgow, Manchester

2024-08-22

Active, closed

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer

Alterome Therapeutics, Inc.

Phase 1

110

London, Manchester, Newcastle upon Tyne, Sutton

2024-08-22

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

675

Plymouth, London, Southampton, Glasgow, Manchester, Newcastle upon Tyne

2024-08-19

Recruiting

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

NCT06600789Solid Malignancies

Carrick Therapeutics Limited

Phase 1/2

Manchester, Oxford, Sutton

2024-08-16

Recruiting

A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive

NCT06433921Asthma, Mild Asthma

GlaxoSmithKline

Phase 1

Manchester

2024-08-14

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

Bath, Glasgow, Leicester, London, Manchester, Oxford, Wolverhampton

2024-08-13

Recruiting

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer

DrugOlaparib

MOMA Therapeutics

Phase 1

220

London, Manchester, Newcastle upon Tyne

2024-08-13

Recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

NCT06292780Relapsed/Refractory Systemic Light Chain Amyloidosis

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

220

London, Manchester

2024-08-07

Active, closed

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06162572Non-small Cell Lung Cancer (NSCLC)

DrugsS095029·Cemiplimab

Servier Bio-Innovation LLC

Phase 1/2

102

London, Manchester

2024-08-07

Recruiting

Study of XB010 in Subjects With Solid Tumors

NCT06545331Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)

DrugPembrolizumab

Exelixis

Phase 1

396

Leicester, London, Manchester

2024-08-06

Recruiting

Study of STP938 (Dencatistat) in Advanced Solid Tumours

NCT06297525Solid Tumor

DrugSTP938

Step Pharma, SAS

Phase 1

Glasgow, London, Manchester

2024-08-02

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Cambridge, Guildford, London, Manchester, Oxford, Swansea, Taunton, Truro

2024-08-01

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

London, Sutton, Glasgow, Leeds, Manchester

2024-07-24

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

London, Manchester, Surrey, Edinburgh

2024-07-19

Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180Advanced Melanoma

DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Nivolumab

Replimune, Inc.

Phase 3

400

Liverpool, London, Manchester

2024-07-11

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

136

Edinburgh, London, Manchester, Oxford

2024-07-09

Active, closed

Versius Paediatrics Study

NCT06539442Robotic Surgical Procedures in Pediatric Urology

CMR Surgical Ltd

Not applicable

150

London, Manchester, Southampton

2024-07-08

Recruiting

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy

Walden Biosciences

Phase 2

Derby, Leicester, London, Manchester, Salford

2024-07-02

Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

Eli Lilly and Company

Phase 1

420

London, Manchester

2024-07-01

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton

2024-06-28

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Cambridge, Cardiff, Glasgow, Liverpool, London, Manchester, Middlesex, Newcastle upon Tyne

2024-06-25

Recruiting

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

NCT06471829Cushing's Disease

DrugLu AG13909

H. Lundbeck A/S

Phase 2

Manchester, Birmingham

2024-06-19

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

London, Romford, Manchester, Sutton, Torquay

2024-06-07

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

London, Manchester, Norwich, Plymouth

2024-06-07

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Oxford, Surrey Quays

2024-06-05

Recruiting

Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976Hypochondroplasia

QED Therapeutics, a BridgeBio company

Observational

150

London, Manchester, Sheffield, Glasgow

2024-06-05

Recruiting

Post-market Prospective Clinical Study of Nagor Perle Mammary Implants

NCT06013514Breast Reconstruction, Breast Reconstruction Following Mastectomy, Breast Revision, Breast Augmentation

GCA (Eurosilicone)

Observational

Manchester

2024-06-01

Active, closed

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms

DrugsTucatinib·Disitamab Vedotin

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

Sutton, London, Manchester

2024-05-20

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Cambridge, Edinburgh, London, Nottingham, Leeds, Manchester

2024-05-19

Active, closed

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugsKeytruda·Pembrolizumab

Inhibrx Biosciences, Inc

Phase 2/3

410

Chelsea, Northwood, Newcastle upon Tyne, Sutton, Aberdeen, Cambridge, Manchester, Norwich

2024-05-14

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

450

Cambridge, Dundee, London, Manchester

2024-05-03

Active, closed

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

NCT06402838Alzheimer's Disease

Hoffmann-La Roche

Phase 2

256

Chertsey, Edinburgh, London, Manchester, Southampton

2024-05-02

Recruiting

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease

DrugVERVE-102

Verve Therapeutics, Inc.

Phase 1

Birmingham, Cambridge, Edinburgh, London, Manchester, Nottingham

2024-04-30

Active, closed

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

NCT06346067Advanced or Metastatic NRAS-mutant Melanoma

DrugsNaporafenib·Temodar·Dacarbazine·Trametinib

Erasca, Inc.

Phase 3

Preston, City of London, Exeter, London, Manchester

2024-04-29

Active, closed

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551Osteogenesis Imperfecta

DrugRomosozumab

Amgen

Phase 3

111

Glasgow, Manchester, Sheffield

2024-04-22

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Paraplatin·Taxol·Keytruda

Janssen Research & Development, LLC

Phase 1/2

287

Cambridge, Guildford, London, Manchester

2024-04-22

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

Cambridge, Glasgow, London, Edinburgh, Manchester

2024-04-10

Recruiting

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor

DrugXmAb541

Xencor, Inc.

Phase 1

282

Manchester

2024-04-04

Active, closed

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

NCT06079372Hypophosphatasia

DrugsAsfotase alfa·ALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

Birmingham, Manchester, Sheffield

2024-04-02

Recruiting

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

NCT06274515Breast Cancer

Hoffmann-La Roche

Phase 4

320

Basingstoke, London, Manchester

2024-04-02

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Birmingham, Cambridge, Cardiff, Leeds, London, Manchester, Metropolitan Borough of Wirral, Southampton

2024-04-01

Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

NCT06435000Stargardt, Stargardt's Disease, Stargardt Disease, STGD1

Splice Bio

Observational

London, Leeds, Manchester, Oxford

2024-03-29

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

Cambridge, Doncaster, Leicester, London, Manchester, Reading, Stevenage

2024-03-29

Active, closed

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767Bladder Cancer

DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

230

Torquay, London, Glasgow, Manchester

2024-03-28

Recruiting

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)

DrugsFT819·Fludara·Bendamustine·Cytoxan

Fate Therapeutics

Phase 1

244

Manchester, Cambridge, London

2024-03-28

Active, closed

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201Multiple Sclerosis, Myasthenia Gravis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

120

Manchester, London, Salford

2024-03-28

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

Glasgow, Cambridge, Edinburgh, Leicester, London, Manchester, Sutton

2024-03-18

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Birmingham, Bristol, Liverpool, London, Manchester, Southampton

2024-03-14

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073Crohn's Disease

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

Glasgow, London, Manchester, Oxford, Sheffield

2024-03-13

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

Edinburgh, Headington, London, Manchester, Sheffield, Whitechapel

2024-03-13

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381Aortic Stenosis

DrugPelacarsen

Novartis Pharmaceuticals

Phase 2

502

Reading, Portadown, Edinburgh, Leicester, Liverpool, London, Londonderry, Manchester

2024-03-07

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Cambridge, London, Manchester, Oxford, Taunton

2024-03-04

Active, closed

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

NCT05737628Lymphoma

DrugsBYON4228·Rituximab

Byondis B.V.

Phase 1

Manchester, Plymouth

2024-03-04

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

London, Glasgow, Manchester, Sutton

2024-02-21

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

London, Manchester

2024-02-20

Recruiting

A Global Prospective Observational Registry of Patients With Pompe Disease

NCT06121011Pompe Disease

DrugsAlglucosidase alfa·Cipaglucosidase alfa·Miglustat·Avalglucosidase alfa

Amicus Therapeutics

Observational

500

Birmingham, Cambridge, Cardiff, London, Manchester, Salford

2024-02-16

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Plymouth, London, Portsmouth, Leeds, Manchester, Newcastle upon Tyne

2024-02-05

Active, closed

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

NCT06333483Systemic Lupus Erythematosus

DrugObecabtagene autoleucel

Autolus Limited

Phase 1

Cambridge, London, Manchester

2024-02-02

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245Advanced Solid Tumors, Colorectal Cancer

DrugsVVD-133214·Avastin·Keytruda·Bevacizumab

Vividion Therapeutics, Inc.

Phase 1

280

London, Manchester, Sutton

2024-01-25

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Cardiff, London, Leeds, Manchester, Newcastle upon Tyne

2024-01-23

Recruiting

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)

DrugsAZD3470·Keytruda·Pembrolizumab

AstraZeneca

Phase 1/2

161

Manchester, Oxford

2024-01-23

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Truro, London, Southampton, Manchester, Maidstone, Middlesex, Nottingham, Bath

2024-01-18

Recruiting

ZNN Bactiguard Antegrade Femoral Nails PMCF Study

NCT05339360Femur Fracture, Osteotomy

Zimmer Biomet

Observational

100

Manchester

2024-01-16

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,181

Birmingham, Cardiff, Glasgow, Hexham, London, Manchester

2024-01-11

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

Cambridge, Truro, Glasgow, London, Manchester

2023-12-31

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Cambridge, Gloucester, Lincoln, Boston, London, Gwent, Windsor, Manchester

2023-12-31

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma

DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Truxima

Bristol-Myers Squibb

Phase 1/2

460

Southampton, Manchester, Edinburgh

2023-12-29

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

London, Manchester, Surrey

2023-12-29

Recruiting

DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit

NCT06645236Metastatic Colorectal Cancer (mCRC)

QIAGEN Gaithersburg, Inc

Not applicable

600

Manchester

2023-12-22

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

Aberdeen, Dundee, Huddersfield, Leeds, Manchester, Northwood, Sheffield, Wolverhampton

2023-12-21

Recruiting

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

NCT06154252Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy

Cabaletta Bio

Phase 2/3

London, Manchester, Salford

2023-12-20

Recruiting

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

NCT05912517Hemolytic Disease of the Fetus and Newborn

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

120

Birmingham, Leeds, London, Manchester, Oxford

2023-12-20

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566CLL/SLL

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 3

400

Birmingham, Bournemouth, Liverpool, London, Manchester, Stoke-on-Trent, Swansea, West Bromwich

2023-12-20

Active, closed

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

200

London, Manchester, Nottingham

2023-12-20

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood

2023-12-14

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugNexiguran ziclumeran

Intellia Therapeutics

Phase 3

1,200

Birmingham, Cardiff, Glasgow, Hexham, Liverpool, London, Manchester

2023-12-13

Active, closed

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

NCT07116889Asthma, COPD (Chronic Obstructive Pulmonary Disease)

DrugGB-0895

Generate Biomedicines

Phase 1

156

London, Manchester, Merthyr Tydfil

2023-12-12

Active, closed

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

NCT06149403MPS-IH (Hurler Syndrome)

Orchard Therapeutics

Phase 3

Manchester

2023-12-11

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

East Sussex, Derby, London, Truro, Glasgow, Manchester

2023-12-06

Recruiting

Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery

NCT06246136Open Angle Glaucoma

Elios Vision, Inc.

Not applicable

194

East Grinstead, Edinburgh, Guildford, London, Manchester

2023-12-05

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

DrugsCamizestrant·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 1/2

564

Cambridge, Leeds, London, Manchester

2023-12-05

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Cambridge, Edgbaston, Glasgow, Scotland, London, Manchester, Sutton

2023-12-04

Active, closed

Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

NCT06150183Advanced Malignant Solid Tumor

DrugBNT314

BioNTech SE

Phase 1

London, Manchester, Newcastle

2023-11-30

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

NCT06166056Bronchiectasis

Chiesi Farmaceutici S.p.A.

Phase 1/2

Cambridge, Dundee, Edinburgh, Glasgow, Leeds, London, Manchester, Southampton

2023-11-29

Active, closed

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

NCT06154837Pulmonary Disease, Chronic Obstructive

DrugGSK3862995B

GlaxoSmithKline

Phase 1

127

Barnsley, Blackpool, Cambridge, Cannock, London, Manchester, West Yorkshire

2023-11-27

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne

2023-11-21

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

NCT06173518Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

DrugAUTO1

Autolus Limited

Phase 1

London, Manchester, Newcastle upon Tyne

2023-11-16

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353Cytomegalovirus (CMV)

DrugMaribavir

Takeda

Phase 3

London, Manchester, Nottingham, Birmingham

2023-11-13

Recruiting

LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.

NCT06193902Tumor, Solid

Leucid Bio

Phase 1/2

London, Manchester

2023-11-13

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588Non-small Cell Lung Cancer (NSCLC)

DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

556

London, Sutton, Manchester, Metropolitan Borough of Wirral

2023-11-12

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab

AstraZeneca

Phase 3

863

Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton

2023-11-09

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees

2023-10-31

Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease

DrugTreprostinil

United Therapeutics

Phase 3

698

Birmingham, Cambridge, Edinburgh, London, Manchester, Perth

2023-10-30

Active, closed

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

1,600

Leeds, London, Manchester

2023-10-26

Recruiting

ZNN Bactiguard Retrograde Femoral Nails PMCF Study

NCT05276674Femoral Fracture

Zimmer Biomet

Observational

100

Leeds, Manchester, Stockport

2023-10-23

Active, closed

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

114

Bournemouth, Glasgow, Headington, Inverness, Leeds, London, Manchester, Plymouth

2023-10-23

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936Lymphoma

DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

182

Glasgow, Lincoln, London, Manchester, Oxford, Plymouth

2023-10-22

Active, closed

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333Congestive Heart Failure

AskBio Inc

Phase 2

150

Manchester, Leeds, Cardiff, Glasgow, London

2023-10-20

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma

DrugObrixtamig

Boehringer Ingelheim

Phase 2

204

Leicester, London, Manchester, Newcastle upon Tyne

2023-10-13

Active, closed

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

NCT06109649Vitiligo

Clinuvel, Inc.

Phase 3

200

London, Manchester

2023-10-11

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386IC-MPGN

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

106

Belfast, Cardiff, London, Manchester, Salford

2023-10-02

Active, closed

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359Myeloproliferative Neoplasms

DrugsINCA033989·Ruxolitinib

Incyte Corporation

Phase 1

160

London, Manchester, Oxford

2023-09-25

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

Birmingham, Cambridge, Liverpool, London, Manchester, Oxford

2023-09-21

By invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

NCT06075537Mucopolysaccharidosis II

DrugTividenofusp alfa

Denali Therapeutics Inc.

Phase 2/3

Birmingham, London, Manchester

2023-09-20

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

Cambridge, Edinburgh, Birmingham, London, Manchester

2023-09-18

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

NCT06047171Glomerulonephritis Rapidly Progressive

DrugsCyclophosphamid·Rituximab

Alentis Therapeutics AG

Phase 2

Birmingham, Cambridge, Liverpool, London, Manchester, Preston

2023-09-07

Active, closed

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

NCT06041269Rheumatoid Arthritis

DrugRosnilimab

AnaptysBio, Inc.

Phase 2

420

London, Manchester

2023-08-31

Active, closed

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)

NCT06254482Huntington Disease

DrugVotoplam

Novartis Pharmaceuticals

Phase 2

144

Birmingham, Cardiff, London, Manchester

2023-08-25

Recruiting

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200Colonic Neoplasms, Neoplasms, Colon

DrugsCapeox·Dostarlimab·Folfox

GlaxoSmithKline

Phase 3

892

Birmingham, Chelmsford, Cheltenham, Edinburgh, Hull, Leeds West Yorkshire, London, Manchester

2023-08-01

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

DrugZipalertinib

Taiho Oncology, Inc.

Phase 2

220

Barnet, London, Manchester, Nottingham

2023-07-31

Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors

DrugsINCA33890·ADG126·Folfox·Cetuximab

Incyte Corporation

Phase 1

570

Cambridge, London, Manchester, Newcastle upon Tyne

2023-07-24

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester

2023-07-19

Active, closed

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

100

Peterborough, Manchester, Southampton

2023-07-11

By invitation

A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study

NCT05777993Pyruvate Kinase Deficiency, Anemia, Hemolytic, Sickle Cell Disease, Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 4

Manchester

2023-07-06

Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Phase 1/2

230

Glasgow, London, Manchester, Newcastle upon Tyne, Oxford

2023-07-06

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Birmingham, Cambridge, Exeter, Leicester, London, Middlesbrough, Torquay, Manchester

2023-06-28

Active, closed

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

NCT05601752Ovarian Cancer

USWM CT, LLC

Phase 2

London, Manchester

2023-06-26

Active, closed

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

NCT05734196Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency

DrugINZ-701

Inozyme Pharma

Phase 1

Manchester

2023-06-25

Recruiting

Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)

NCT05967143Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)

Sirtex Medical

Observational

845

Manchester, London

2023-06-19

Recruiting

A Retrospective Study to Characterize Participants With Propionic Acidemia

NCT05769621Propionic Acidemia

ModernaTX, Inc.

Observational

Kirkcaldy, Manchester, City of London, Birmingham

2023-06-16

Active, closed

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

NCT05898620Rett Syndrome

Neurogene Inc.

Phase 3

Edinburgh, Manchester

2023-06-13

Active, closed

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

398

Guildford, Bebington, London, Manchester, Sutton

2023-06-01

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

London, Manchester

2023-05-31

Active, closed

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis

DrugPegcetacoplan

Apellis Pharmaceuticals, Inc.

Phase 3

100

London, Manchester, Nottingham

2023-05-29

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT05442567Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

240

London, Cardiff, Birmingham, Manchester

2023-05-16

Recruiting

Multicenter Glaucoma Study Investigating Standalone Canaloplasty

NCT05786196Primary Open Angle Glaucoma

Nova Eye, Inc.

Not applicable

Edinburgh, Liverpool, Manchester

2023-05-09

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

London, Manchester, Nottingham

2023-05-08

Active, closed

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

NCT05552469Myeloid Diseases

Novartis Pharmaceuticals

Phase 1

Cardiff, London, Manchester

2023-05-08

Active, closed

Phase III Study of AK112 for NSCLC Patients

NCT06396065Non-Squamous Non-small Cell Lung Cancer

DrugsIvonescimab·Pemetrexed·Carboplatin

Summit Therapeutics

Phase 3

420

London, Manchester

2023-05-04

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

Birmingham, Glasgow, London, Manchester, Newcastle upon Tyne

2023-05-03

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer

Genentech, Inc.

Phase 1

210

Cambridge, Leicester, Manchester, Sutton

2023-05-02

Active, closed

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

NCT05466799Locally Advanced Pancreatic Cancer

OncoSil Medical Limited

Phase 2

London, Manchester, Newcastle upon Tyne, Southampton

2023-04-26

Active, closed

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine

AstraZeneca

Phase 2

294

Cambridge, London, Manchester

2023-04-24

Active, closed

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501Renal Cell Carcinoma

DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda

Hoffmann-La Roche

Phase 2

199

London, Manchester

2023-04-21

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

NCT05685173B-cell Non-Hodgkins Lymphoma (B-NHL)

DrugOdronextamab

Regeneron Pharmaceuticals

Phase 1

107

Truro, Southampton, Edinburgh, Manchester

2023-04-20

Active, closed

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180Asthma

DrugBenralizumab

AstraZeneca

Phase 3

London, Manchester

2023-04-05

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma

AbbVie

Phase 1

Leeds, London, Manchester

2023-04-04

Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632Multiple Myeloma

DrugEtentamig

AbbVie

Phase 1

210

London, Manchester

2023-03-21

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

Cheltenham, London, Northwood, Southampton, Sutton, Manchester, Swansea

2023-03-15

Active, closed

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

NCT05705349HIV-1 Infection

DrugsDOR/ISL·B/F/TAF

Merck Sharp & Dohme LLC

Phase 3

537

Bristol, London, Manchester

2023-03-08

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

London, Blackburn, Glasgow, Manchester

2023-03-03

Recruiting

Magseed Pro(R)/ Sentimag(R) Gen3

NCT05142787Breast Cancer

Endomagnetics Ltd.

Not applicable

224

London, Manchester

2023-03-02

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Birmingham, Leeds, Liverpool, Manchester, Newcastle upon Tyne, Oxford, Southampton, Belfast

2023-02-27

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

Fore Biotherapeutics

Phase 2

254

Manchester, London

2023-02-21

Active, closed

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

NCT05741476Allergy, Peanut

DBV Technologies

Phase 3

600

London, Manchester, Sheffield, Southampton

2023-02-21

Active, closed

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

NCT05797896Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration

Complement Therapeutics

Observational

250

Belfast, Bradford, Frimley, Gloucester, Liverpool, London, Manchester, Newcastle

2023-02-07

Active, closed

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack

DrugDexpramipexole Dihydrochloride

Areteia Therapeutics

Phase 3

600

Bellshill, Birmingham, Bollington, Chorley, Enfield, Liverpool, London, Manchester

2023-01-30

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London

2023-01-23

Active, closed

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,564

Exeter, Edinburgh, Bristol, Sutton, Coventry, London, Manchester, Taunton

2023-01-16

Recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

DrugsVepugratinib·Digoxin·Enfortumab Vedotin·Rosuvastatin

Eli Lilly and Company

Phase 1

677

Manchester, Sheffield

2023-01-12

Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

NCT06198712Sickle Cell Disease

DrugEtavopivat

Forma Therapeutics, Inc.

Phase 2

London, Manchester

2023-01-12

Recruiting

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

DrugsElacestrant·Exemestane·Everolimus·Abemaciclib

Ellipses Pharma

Phase 1/2

London, Manchester, Liverpool

2023-01-11

Active, closed

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease

DrugGSK4532990

GlaxoSmithKline

Phase 2

284

Nottingham, Cannock, London, Manchester, Newcastle upon Tyne

2023-01-02

Active, closed

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266NSCLC

DrugsDato-DXd·Durvalumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 3

1,350

Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough

2022-12-29

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Cambridge, Manchester, Birmingham, Leeds, London, Middlesex, Sutton

2022-12-19

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

Woodhurst, Huddersfield, Blackpool, Hull, Liskeard, Manchester, Newquay, Poole

2022-12-13

Active, closed

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

NCT05529316Advanced Melanoma

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

150

London, Manchester, Middlesex

2022-12-12

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654Triple Negative Breast Cancer

DrugsXeloda·Sacituzumab Govitecan·Keytruda·Capecitabine

Gilead Sciences

Phase 3

1,514

Cottingham, Edgbaston, Liverpool, London, Manchester, Northwood, Taunton, York

2022-12-12

Recruiting

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

NCT05611801Hemophilia A, Hemophilia B

DrugMarstacimab

Pfizer

Phase 3

100

Newcastle upon Tyne, Birmingham, London, Manchester

2022-12-09

Active, closed

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886Breast Cancer

DrugsGedatolisib·Alpelisib·Palbociclib·Fulvestrant

Celcuity Inc

Phase 3

701

Bath, Cardiff, London, Manchester, Nottingham, Sutton

2022-12-08

By invitation

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

1,400

Bellshill, Edgbaston, Manchester, Cardiff, Hampstead, Liverpool, London

2022-11-30

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne

2022-11-28

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

London, Manchester, Nottingham, Glasgow

2022-11-08

Active, closed

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT05170204Non-Small Cell Lung Cancer

DrugsEntrectinib·Alectinib·Durvalumab

Hoffmann-La Roche

Phase 3

Manchester

2022-11-01

Active, closed

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

NCT05434156Healthy Volunteers, Major Depressive Disorder, Depression

Eleusis Therapeutics

Phase 1/2

Liverpool, Manchester

2022-10-27

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester

2022-10-24

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

NCT05372354Multiple Myeloma

DrugsBMS-986158·Tazemetostat·Mezigdomide·Trametinib

Bristol-Myers Squibb

Phase 1/2

260

Manchester, Leicester, Liverpool, Oxford, London

2022-10-18

Active, closed

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237Non-small Cell Lung Cancer

DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed

Gilead Sciences

Phase 3

1,021

London, Manchester

2022-10-12

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

129

Manchester, Sutton

2022-10-11

Active, closed

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903Leukemia, Myeloid, Acute

DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine

Janssen Research & Development, LLC

Phase 1

196

London, Manchester, Oxfordshire

2022-10-04

Active, closed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054Breast Neoplasms

DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole

Eli Lilly and Company

Phase 3

8,000

Colchester, East Kilbride, Glasgow, Edinburgh, Liverpool, London, Manchester, Northwood, Plymouth

2022-10-04

Recruiting

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126NSCLC

DrugPemetrexed

Ellipses Pharma

Phase 1/2

265

London, Manchester, Sheffield

2022-09-30

Active, closed

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

DrugsMIRV·Mirvetuximab Soravtansine·Carboplatin

AbbVie

Phase 2

125

London, Northwood, Nottingham, Taunton, Sutton, Manchester

2022-09-28

Active, closed

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093Relapsed/Refractory Follicular Lymphoma

DrugsAxi-cel·Axicabtagene Ciloleucel·Bendamustine·Vincristine

Kite, A Gilead Company

Phase 3

231

Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton

2022-09-22

Active, closed

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

NCT05461170Hepatitis D, Chronic

DrugsTobevibart·Elebsiran

Vir Biotechnology, Inc.

Phase 2

Birmingham, London, Manchester

2022-09-17

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

London, Manchester, Birmingham, Leeds

2022-09-13

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Cambridge, Dundee, London, Manchester

2022-09-06

Active, closed

Post-market Clinical Follow-up (PMCF) Study of the Poly-Tape Devices for Medial Patellofemoral Ligament (MPFL) Reconstruction

NCT05264389Medial Patellofemoral Dislocation

Xiros Ltd

Observational

Great Yarmouth, Manchester, Stoke-on-Trent, Winchester, Yeovil

2022-09-05

Recruiting

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697Advanced Solid Tumors

DrugsIpilimumab·Nivolumab·Pembrolizumab

ModernaTX, Inc.

Phase 1/2

361

Preston, Glasgow, Birmingham, London, Manchester, Oxford, Southampton

2022-09-01

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

Leicester, Liverpool, London, Manchester

2022-08-31

Active, closed

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

Biogen

Phase 2

416

London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol

2022-08-24

Active, closed

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma

DrugsAvelumab·Sacituzumab Govitecan

EMD Serono Research & Development Institute, Inc.

Phase 2

256

London, Manchester, Northwood, Preston

2022-08-17

Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705Obstructive Hypertrophic Cardiomyopathy

DrugMavacamten

Bristol-Myers Squibb

Observational

1,700

London, Manchester, Liverpool, Birmingham, Leeds, Cardiff

2022-08-16

Active, closed

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Janssen Research & Development, LLC

Phase 1/2

166

London, Manchester

2022-08-12

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Cambridge, Chelsea, Manchester, Northwood

2022-08-11

Active, closed

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS

DrugsNorditropin·Somapacitan

Novo Nordisk A/S

Phase 3

412

Cambridge, Hull, Liverpool, London, Manchester, Tooting

2022-08-10

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus

Genentech, Inc.

Phase 3

373

Dorchester, London, Manchester, Nottingham

2022-08-03

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

London, Manchester, Wolverhampton

2022-08-03

Recruiting

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

NCT05463263Lymphoma, B-Cell, Lymphoma, T-Cell

DrugSTP938

Step Pharma, SAS

Phase 1/2

180

Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton

2022-08-03

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

DrugsZilovertamab vedotin·Nemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

189

Truro, London, Oxford, Manchester

2022-07-21

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton

2022-07-08

Recruiting

A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

NCT05163288Niemann-Pick Disease, Type C

DrugN-Acetyl-L-Leucine

IntraBio Inc

Phase 3

London, Manchester

2022-06-30

Active, closed

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms

DrugsNab-paclitaxel /m^2·Relacorilant

Corcept Therapeutics

Phase 3

381

Brighton, Taunton, Cheltenham, London, Manchester, Northwood

2022-06-29

Active, closed

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

NCT05181618Severe Hemophilia A, Moderate Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 4

136

London, Manchester

2022-06-20

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632Adult Acute Myeloid Leukemia

Priothera SAS

Phase 3

366

Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford

2022-06-16

Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam

Nuvalent Inc.

Phase 1/2

840

Sutton, Edinburgh, London, Manchester

2022-06-09

Active, closed

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

NCT05367440Metastatic Prostate Cancer

DrugsSaruparib·Zytiga·Apalutamide·Xtandi

AstraZeneca

Phase 1/2

174

Cambridge, Glasgow, Manchester, Plymouth

2022-06-02

Active, closed

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

NCT05428969Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML

DrugsBexmarilimab·Venclyxto·Azacitidine·Venetoclax

Faron Pharmaceuticals Ltd

Phase 1/2

181

Manchester, Truro

2022-06-02

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

London, Manchester, Newcastle upon Tyne

2022-05-23

Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml

DrugELVN-001

Enliven Therapeutics

Phase 1

250

Glasgow, London, Manchester

2022-05-22

Active, closed

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254Metastatic Melanoma, Unresectable Melanoma

DrugsIO102-IO103·Pembrolizumab

IO Biotech

Phase 3

407

London, Manchester, Oxford

2022-05-17

Active, closed

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

NCT04732416Congenital Hyperinsulinism

Hanmi Pharmaceutical Company Limited

Phase 2

London, Manchester

2022-05-05

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

372

Glasgow, Cambridge, London, Manchester, Merseyside

2022-05-03

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer

DrugsBezuclastinib·Sunitinib·Midazolam

Cogent Biosciences, Inc.

Phase 3

482

Cambridge, Glasgow, London, Manchester, Sheffield

2022-04-14

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)

DrugBexobrutideg

Nurix Therapeutics, Inc.

Phase 1

572

Manchester, Glasgow, Leeds, Liverpool, London, Oxford, Plymouth, Southampton

2022-04-13

Recruiting

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

NCT05329532Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck

DrugPembrolizumab

Scancell Ltd

Phase 1/2

168

Brighton, Cardiff, Edinburgh, Guildford, London, Manchester, Nottingham, Preston

2022-04-07

Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

NCT05312879Proteinuric Kidney Disease

Vertex Pharmaceuticals Incorporated

Phase 2/3

466

Basildon, Bellshill, Birmingham, Carshalton, Leicester, London, Manchester, Nottingham

2022-03-30

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

London, Manchester, Nottingham, Glasgow

2022-03-28

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton

2022-03-25

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846Non Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab vedotin·Docetaxel

AbbVie

Phase 3

768

London, Nottingham, Birmingham, Manchester

2022-03-25

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide

Merck Sharp & Dohme LLC

Phase 3

460

Manchester, Northwood, Birmingham

2022-03-24

Active, closed

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051Neoplasms

DrugsRemzistotug·GSK5764227·Nelistotug·Belrestotug

GlaxoSmithKline

Phase 1

152

Manchester, Sutton

2022-03-22

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

London, Nottingham, Glasgow, Manchester, Swansea

2022-03-15

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

NCT05315700Solid Tumors

ORIC Pharmaceuticals

Phase 1/2

350

Manchester

2022-03-10

Recruiting

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

NCT05295433Methylmalonic Acidemia

ModernaTX, Inc.

Phase 1/2

Birmingham, Manchester

2022-03-08

Active, closed

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures

DrugFintepla

Zogenix, Inc.

Phase 3

Bristol, London, Manchester, Sheffield

2022-03-08

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DrugsMosunetuzumab·Venclyxto·Venclexta·Tocilizumab

Hoffmann-La Roche

Phase 1

332

Manchester, Oxford

2022-03-07

Active, closed

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582HER2 Positive Breast Cancer

DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

654

London, Sutton, Manchester

2022-03-07

Recruiting

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes

DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax

Sumitomo Pharma America, Inc.

Phase 1/2

606

Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton

2022-02-28

Active, closed

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809Osteogenesis Imperfecta

DrugSetrusumab

Ultragenyx Pharmaceutical Inc

Phase 2/3

183

Manchester, Sheffield

2022-02-21

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

NCT05031780Sickle Cell Disease

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 2/3

286

London, Cambridge, Manchester

2022-02-11

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320Crohn's Disease (CD)

DrugVedolizumab

Takeda

Phase 3

120

London, Cardiff, Birmingham, Manchester

2022-02-10

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

Manchester, Glasgow, London

2022-02-03

Active, closed

ADH1 and ADH2 Disease Monitoring Study (DMS)

NCT05227287Autosomal Dominant Hypocalcemia

Calcilytix Therapeutics, Inc., a BridgeBio company

Observational

Manchester

2022-01-20

Recruiting

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor

Nuvalent Inc.

Phase 1/2

359

London, Manchester

2022-01-04

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

194

Cambridge, Manchester, London

2021-12-20

By invitation

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

NCT05145010Achondroplasia

DrugInfigratinib

QED Therapeutics, a BridgeBio company

Phase 2

300

Birmingham, Bristol, Glasgow, London, Manchester, Sheffield

2021-12-06

Active, closed

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016Relapsed/Refractory Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

222

London, Manchester

2021-12-01

Active, closed

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

NCT04924608Neurofibromatosis 1, Plexiform Neurofibroma (PN)

DrugSelumetinib

AstraZeneca

Phase 3

145

London, Manchester

2021-11-19

Active, closed

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

NCT05130450Familial Chylomicronemia Syndrome

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

Manchester

2021-11-18

Active, closed

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734Non-Small Cell Lung Cancer

DrugsSacituzumab Govitecan·Docetaxel

Gilead Sciences

Phase 3

603

Birmingham, Colchester, Glasgow, Leeds, Leicester, London, Manchester

2021-11-17

Active, closed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

776

Cardiff, Edinburgh, London, Manchester

2021-11-17

Recruiting

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

NCT05130437Propionic Acidemia

DrugMRNA-3927

ModernaTX, Inc.

Phase 1/2

Manchester, Birmingham, London

2021-11-09

Recruiting

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

NCT05104515Prostate Cancer, Non Small Cell Lung Cancer, Ovarian Cancer

Oxford Vacmedix UK Ltd.

Phase 1

London, Manchester, Oxford

2021-11-01

Active, closed

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296Systemic Lupus Erythematosus

DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Methylprednisolone·Obinutuzumab

Hoffmann-La Roche

Phase 3

303

Cambridge, Leeds, London, Manchester

2021-10-26

Recruiting

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

NCT04833894Generalized Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 2/3

London, Manchester, Oxford

2021-10-26

Recruiting

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223Metastatic Colorectal Cancer

DrugsDivarasib·Tiragolumab·Inavolisib·Tecentriq

Hoffmann-La Roche

Phase 1

542

Cambridge, Cardiff, London, Manchester, Sutton

2021-10-22

Active, closed

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

NCT04857372Mesothelioma

Novartis Pharmaceuticals

Phase 1

137

Manchester

2021-10-21

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

Blackpool, Bristol, Cardiff, Colchester, Edinburgh, London, Manchester, Nottingham

2021-10-18

Active, closed

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696Systemic Lupus Erythematosus

Beeline Medicines Corporation

Phase 2

248

Cambridge, Bradford, Manchester

2021-10-11

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Bournemouth, Oxford, Cardiff, Bristol, Canterbury, Manchester

2021-10-04

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma

DrugPaclitaxel

Nurix Therapeutics, Inc.

Phase 1

345

Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford

2021-09-29

Active, closed

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075Conventional Chondrosarcoma

DrugINBRX-109

Inhibrx Biosciences, Inc

Phase 2

206

London, Manchester, Oxford

2021-09-23

Active, closed

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT05050097Multiple Myeloma

DrugsTalquetamab·Carfilzomib·Pomalidomide·Daratumumab

Janssen Research & Development, LLC

Phase 1

166

London, Manchester, Oxford, Surrey

2021-09-22

Active, closed

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

NCT04776252HIV-1 Infection

DrugDOR/ISL

Merck Sharp & Dohme LLC

Phase 3

2,000

East Sussex, Bristol, London, Manchester

2021-09-15

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

NCT04774718ALK Fusion-positive Solid or CNS Tumors

DrugAlectinib

Hoffmann-La Roche

Phase 1/2

London, Manchester, Newcastle upon Tyne

2021-09-14

Active, closed

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

NCT04973163Solid Tumors, KRAS Mutation

DrugsBI 1701963·Midazolam

Boehringer Ingelheim

Phase 1

Manchester

2021-09-09

Active, closed

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa

NCT04910776Glycogen Storage Disease Type II

DrugAvalglucosidase alfa

Sanofi

Phase 3

London, Manchester

2021-09-01

Active, closed

A Study of AL102 in Patients With Progressing Desmoid Tumors

NCT04871282Desmoid, Desmoid Tumor

Immunome, Inc.

Phase 2/3

198

Edinburgh, Cambridge, London, Manchester

2021-09-01

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

Barnet, Bradford, Coventry, Leeds, Manchester, Newcastle, Stoke-on-Trent

2021-08-30

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

London, Manchester, Newcastle upon Tyne, Nottingham, Preston, Sheffield, Surrey Quays, Glasgow

2021-08-19

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Birmingham, Bristol, Leeds, London, Manchester, Surrey

2021-08-19

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis

DrugSparsentan

Travere Therapeutics, Inc.

Phase 2

Bristol, Glasgow, Liverpool, London, Manchester

2021-08-12

Active, closed

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05005975EPP, XLP

Tanabe Pharma America, Inc.

Phase 3

286

Manchester, London

2021-08-10

Recruiting

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288Renal Allograft Recipients

DrugsCyclosporine A·Belatacept·Mycophenolate Mofetil·Tacrolimus

Bristol-Myers Squibb

Phase 3

102

Manchester, Nottingham

2021-07-21

Active, closed

Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

NCT04798768Tachycardia, Ventricular, Arrhythmia, Ventricular

Boston Scientific Corporation

Not applicable

297

Leeds, Liverpool, Manchester, Southampton

2021-07-20

Active, closed

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer

Avacta Life Sciences Ltd

Phase 1

158

Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield

2021-07-16

Active, closed

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

NCT04908189Psoriatic Arthritis

DrugsApremilast·Deucravacitinib

Bristol-Myers Squibb

Phase 3

729

London, Bradford, Hull, Liverpool, Manchester

2021-07-15

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

Blackpool, Cambridge, London, Manchester, Newport, Nottingham, Portsmouth, Reading

2021-06-30

Active, closed

Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

NCT04411654Gaucher Disease, Type 2

DrugsSirolimus·Methylprednisolone·Prednisone

Prevail Therapeutics

Phase 1/2

Manchester

2021-06-29

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Truro, Leicester, London, Manchester, Blackpool, Londonderry

2021-06-18

Active, closed

A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

NCT04848779Glycogen Storage Disease Type II

DrugAlglucosidase alfa

Sanofi

Observational

London, Manchester

2021-06-10

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Birmingham, Cambridge, Cardiff, Dundee, Glasgow, Liverpool, London, Manchester

2021-05-21

Recruiting

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560Acute Leukemia

DrugBleximenib

Janssen Research & Development, LLC

Phase 1/2

420

Cardiff, Leeds, Liverpool, London, Manchester, Oxfordshire, Plymouth

2021-05-19

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-uk/city/manchester

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 12 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 668 of those studies with a site in Manchester.

How many clinical trials are recruiting in Manchester?

335 of the 668 studies on this page are recruiting new participants as of the 12 Oct 2026, 03:15 UTC sync. A further 9 have not yet opened recruitment, 312 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Manchester), 668 studies
Phase	Studies	Recruiting	Share
Phase 3	286	123	42.8%
Phase 2	107	45	16%
Phase 1/2	87	62	13%
Phase 1	81	39	12.1%
Observational	51	34	7.6%
Phase 2/3	27	17	4%
Not applicable	19	10	2.8%
Phase 4	10	5	1.5%

Most active sponsors

Lead sponsors with the most studies (Manchester)
Lead sponsor	Studies	Recruiting
AstraZeneca	74	31
Merck Sharp & Dohme LLC	37	15
Janssen Research & Development, LLC	27	11
Hoffmann-La Roche	25	7
Eli Lilly and Company	17	13
AbbVie	16	7
Bristol-Myers Squibb	15	13
GlaxoSmithKline	14	10
Novartis Pharmaceuticals	12	3
Pfizer	11	8

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.